Chiesi Farmaceutici SpA – Company Profile and SWOT Analysis

Chiesi Farmaceutici SpA – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with a focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and conducts research and development activities in its R&D center in Parma and at laboratories in Paris (France), Chippenham (the UK), Cary (the US) and Lidingo (Sweden). Chiesi is headquartered in Parma, Emilia-Romagna, Italy.

Scope

• Detailed information on Chiesi Farmaceutici SpA required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Chiesi Farmaceutici SpA in the form of a SWOT analysis

• An in-depth view of the business model of Chiesi Farmaceutici SpA including a breakdown and examination of key business segments

• News about Chiesi Farmaceutici SpA, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Chiesi Farmaceutici SpA and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Chiesi Farmaceutici SpA as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Chiesi Farmaceutici SpAs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Cosmo Pharmaceuticals NV

Newron Pharmaceuticals SpA

FB Health SpA

SIFI SpA

Zambon Italia Srl

Siena Biotech SpA

Recordati SpA

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Chiesi Farmaceutici SpA - Key Facts

Chiesi Farmaceutici SpA - Key Employees

Chiesi Farmaceutici SpA - Key Employee Biographies

Chiesi Farmaceutici SpA - Major Products and Services

Chiesi Farmaceutici SpA - History

Chiesi Farmaceutici SpA - Company Statement

Chiesi Farmaceutici SpA - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 – Company Analysis

Company Overview

Chiesi Farmaceutici SpA - Business Description

R&D Overview

Chiesi Farmaceutici SpA - Corporate Strategy

Chiesi Farmaceutici SpA - SWOT Analysis

SWOT Analysis - Overview

Chiesi Farmaceutici SpA - Strengths

Chiesi Farmaceutici SpA - Weaknesses

Chiesi Farmaceutici SpA - Opportunities

Chiesi Farmaceutici SpA - Threats

Chiesi Farmaceutici SpA - Key Competitors

Section 3 – Company’s Lifesciences Financial Deals and Alliances

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Chiesi Farmaceutici SpA, Recent Deals Summary

Section 4 – Company’s Recent Developments

Apr 05, 2023: Chiesi's international growth continues

Apr 04, 2023: Chiesi Global Rare Diseases announces collaboration with the National Alliance on Mental Illness to offer mental health resources for Fabry disease

Jan 30, 2023: Chiesi appoints Giuseppe Accogli as new Group CEO

Jan 09, 2023: Chiesi Farmaceutici agrees to buy Amryt Pharma for $1.48bn

Dec 02, 2022: Chiesi USA sponsors ASHP advantage initiative to support pharmacy technician recruitment and retention

Sep 02, 2022: Chiesi Global rare diseases announces presentations on lysosomal storage diseases at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

Apr 01, 2022: Chiesi group continues growth

Section 5 – Appendix

Methodology

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Chiesi Farmaceutici SpA, Key Facts

Chiesi Farmaceutici SpA, Key Employees

Chiesi Farmaceutici SpA, Key Employee Biographies

Chiesi Farmaceutici SpA, Major Products and Services

Chiesi Farmaceutici SpA, History

Chiesi Farmaceutici SpA, Other Locations

Chiesi Farmaceutici SpA, Subsidiaries

Chiesi Farmaceutici SpA, Joint Venture

Chiesi Farmaceutici SpA, Key Competitors

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Chiesi Farmaceutici SpA, Recent Deals Summary

List of Figures

List of Figures

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports